P
Paul M. Hassoun
Researcher at Johns Hopkins University
Publications - 308
Citations - 16671
Paul M. Hassoun is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Pulmonary hypertension & Medicine. The author has an hindex of 61, co-authored 267 publications receiving 14372 citations. Previous affiliations of Paul M. Hassoun include Johns Hopkins University School of Medicine.
Papers
More filters
Journal ArticleDOI
Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension
Stephen C. Mathai,Monica Bueso,Laura K. Hummers,Danielle Boyce,Noah Lechtzin,J. Le Pavec,Arantza Campo,Hunter C. Champion,Traci Housten,Paul R. Forfia,Ari L. Zaiman,F. M. Wigley,Reda E. Girgis,Paul M. Hassoun +13 more
TL;DR: This is the first description showing NT-proBNP levels are significantly higher in PAH-SSc than IPAH despite less severe haemodynamic perturbations, and stronger predictors of survival in PAh-S sc, suggesting that neurohormonal regulation may differ between PAH -SSc and IPAH.
Journal ArticleDOI
Systemic sclerosis–related pulmonary hypertension associated with interstitial lung disease: Impact of pulmonary arterial hypertension therapies
Jérôme Le Pavec,Reda E. Girgis,Noah Lechtzin,Stephen C. Mathai,David Launay,Laura K. Hummers,Ari L. Zaiman,Olivier Sitbon,Gérald Simonneau,Marc Humbert,Paul M. Hassoun +10 more
TL;DR: This retrospective analysis of consecutive SSc patients from 2 large referral centers who had PH-ILD confirmed by right-sided heart catheterization and who received targeted PAH therapies concluded that there were no clear benefits from these therapies and Deterioration in oxygenation was an important determinant of long-term survival.
Journal ArticleDOI
Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
Neal F. Chaisson,Paul M. Hassoun +1 more
TL;DR: An up-to-date, focused review of SSc-PAH and how it differs from IPAH, including pathogenesis, appropriate screening for disease onset, and new approaches to treatment and longitudinal assessment of this disease are provided.
Journal ArticleDOI
Myocardial delayed enhancement in pulmonary hypertension: pulmonary hemodynamics, right ventricular function, and remodeling.
Monda L. Shehata,Dirk Lossnitzer,Jan Skrok,Danielle Boyce,Noah Lechtzin,Stephen C. Mathai,Reda E. Girgis,Nael F. Osman,Joao A.C. Lima,David A. Bluemke,Paul M. Hassoun,Jens Vogel-Claussen +11 more
TL;DR: In patients with suspected pulmonary hypertension, total delayed enhancement burden at the RV septal insertions is predicted by RV remodeling in response to increased afterload.
Journal ArticleDOI
Regression of chronic hypoxic pulmonary hypertension by simvastatin
Reda E. Girgis,Shehzin Mozammel,Hunter C. Champion,Dechun Li,Dechun Li,Xinqi Peng,Larissa A. Shimoda,Rubin M. Tuder,Roger A. Johns,Paul M. Hassoun +9 more
TL;DR: It is concluded that simvastatin attenuates and induces regression of established CHPH through inhibition of HMG-CoA reductase, and inhibition of ROCK expression and activity may be an important mechanism of statin effect.